Francesco Costa

Government, Health and Not for Profit

Biography

Latest publications

BORSOI L., ARMENI P., Donin G., COSTA F., Ferini-Strambi L. The invisible costs of obstructive sleep apnea (OSA): Systematic review and cost-of-illness analysis Plos One, 2022, vol.17, no. 5, pp.e0268677
ARMENI P., BERTOLANI A., BORSOI L., COSTA F. La spesa sanitaria: composizione ed evoluzione in Rapporto OASI 2021 CERGAS (Eds),Egea, chap. 3, pp.117-173, 2021
TARRICONE R., AMATUCCI F., ARMENI P., BANKS H., BORSOI L., CALLEA G., CIANI O., COSTA F., FEDERICI C. B., TORBICA A., Marletta M. Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies Health Policy, 2021, vol.125, no. 5, pp.602-608
JOMMI C., ARMENI P., BERTOLANI A., COSTA F., OTTO M. The future of Funds for Innovative Medicines: results from a Delphi Study Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2021, vol.8, pp.22-28
ARMENI P., BORSOI L., FORNARO G., JOMMI C., COLOMBO N., COSTA F. Cost-Effectiveness and Net Monetary Benefit of olaparib Maintenance Therapy Versus No Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-Mutated Ovarian Cancer in the Italian National Health Service Clinical Therapeutics, 2020, vol.42, no. 7, pp.1192-1209
ARMENI P., BORSOI L., FORNARO G., JOMMI C., Grossi F., COSTA F. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service Clinical Therapeutics, 2020, vol.42, no. 5, pp.830-847